As of 10:16am ET
| +0.14 / +1.52%|
The 2 analysts offering 12-month price forecasts for Novelion Therapeutics Inc have a median target of 10.25, with a high estimate of 10.50 and a low estimate of 10.00. The median estimate represents a +9.51% increase from the last price of 9.36.
The current consensus among 2 polled investment analysts is to Outperform stock in Novelion Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.